drugset / Trial / NCT04540185

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

NCT04540185

Phase 3 Unknown 3600 enrolled Biomed Industries, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.

Timeline

Start
2020-11-01
Primary completion
2022-11-01
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CYCLO(PROLYLGLYCYL) Small molecule 30 mg Oral
Subject Oral Polio Vaccine Vaccine 0.1 ml Oral